GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Indianapolis-based Lilly has already sued more than two dozen medical spas ... 2025 Chinese tech company Alibaba on Wednesday released a new version of its Qwen 2.5 artificial intelligence ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%. At the same ...

Lilly's progress against Wegovy -- combined with its diverse and growing medical portfolio -- make the company hard to pass up. I think Lilly is a no-brainer opportunity for investors with a long ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

Lilly's financial closing procedures and as a result, the company's final results may vary materially from the preliminary results included in this press release. The preliminary financial ...